Novel |
GSK3B |
glycogen synthase kinase 3 beta |
- Degradation of beta-catenin by the destruction complex
- Beta-catenin phosphorylation cascade
- AKT phosphorylates targets in the cytosol
- Regulation of HSF1-mediated heat shock response
- CRMPs in Sema3A signaling
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- B-WICH complex positively regulates rRNA expression
- Signaling by GSK3beta mutants
- CTNNB1 S33 mutants aren't phosphorylated
- CTNNB1 S37 mutants aren't phosphorylated
- CTNNB1 S45 mutants aren't phosphorylated
- CTNNB1 T41 mutants aren't phosphorylated
- APC truncation mutants have impaired AXIN binding
- AXIN missense mutants destabilize the destruction complex
- Truncations of AMER1 destabilize the destruction complex
- Degradation of GLI2 by the proteasome
- GLI3 is processed to GLI3R by the proteasome
- Constitutive Signaling by AKT1 E17K in Cancer
- Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
- Ubiquitin-dependent degradation of Cyclin D
- Regulation of RUNX2 expression and activity
- Maturation of nucleoprotein
- Maturation of nucleoprotein
- GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2
- Transcriptional and post-translational regulation of MITF-M expression and activity
- GSK3B-mediated proteasomal degradation of PD-L1(CD274)
|
- Lithium cation
- 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
- SB-409513
- AR-AO-14418
- Staurosporine
- Indirubin-3'-monoxime
- 6-bromoindirubin-3'-oxime
- Alsterpaullone
- Phosphoaminophosphonic Acid-Adenylate Ester
- 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
- 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
- (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
- N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
- 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
- 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one
- N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
- 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
- ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
- (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
- Fostamatinib
- Tideglusib
- Lithium citrate
- Lithium succinate
- Lithium carbonate
|
|
Novel |
HRAS |
HRas proto-oncogene, GTPase |
- SOS-mediated signalling
- Activation of RAS in B cells
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB4 signaling
- Signaling by SCF-KIT
- Signalling to RAS
- p38MAPK events
- p38MAPK events
- GRB2 events in EGFR signaling
- SHC1 events in EGFR signaling
- Downstream signal transduction
- GRB2 events in ERBB2 signaling
- GRB2 events in ERBB2 signaling
- Tie2 Signaling
- EGFR Transactivation by Gastrin
- DAP12 signaling
- SHC-related events triggered by IGF1R
- FCERI mediated MAPK activation
- NCAM signaling for neurite out-growth
- EPHB-mediated forward signaling
- Ras activation upon Ca2+ influx through NMDA receptor
- VEGFR2 mediated cell proliferation
- CD209 (DC-SIGN) signaling
- Constitutive Signaling by EGFRvIII
- SHC-mediated cascade:FGFR1
- FRS-mediated FGFR1 signaling
- SHC-mediated cascade:FGFR2
- FRS-mediated FGFR2 signaling
- SHC-mediated cascade:FGFR3
- FRS-mediated FGFR3 signaling
- FRS-mediated FGFR4 signaling
- SHC-mediated cascade:FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- Signaling by FGFR3 in disease
- Regulation of RAS by GAPs
- RAF activation
- RAF/MAP kinase cascade
- MAP2K and MAPK activation
- Negative regulation of MAPK pathway
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- RAS signaling downstream of NF1 loss-of-function variants
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Insulin receptor signalling cascade
- PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
- MET activates RAS signaling
- Activated NTRK2 signals through RAS
- Erythropoietin activates RAS
- Activated NTRK2 signals through FRS2 and FRS3
- Activated NTRK3 signals through RAS
- FLT3 Signaling
- Constitutive Signaling by Overexpressed ERBB2
- Estrogen-stimulated signaling through PRKCZ
- RAS processing
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 ITD and TKD mutants
- Signaling by RAS GAP mutants
- Signaling by RAS GTPase mutants
|
- Hexane-1,6-Diol
- Trifluoroethanol
- Guanosine-5'-Triphosphate
- Guanosine-5'-Diphosphate
- N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
- Ursolic acid
|
- Penile cancer
- Cervical cancer
- Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
- Hepatocellular carcinoma
- Thyroid cancer
- Squamous cell carcinoma
- Bladder cancer
|
Novel |
IRS1 |
insulin receptor substrate 1 |
- PI3K Cascade
- IRS-mediated signalling
- SOS-mediated signalling
- SOS-mediated signalling
- PIP3 activates AKT signaling
- Interleukin-7 signaling
- PI3K/AKT activation
- PI3K/AKT activation
- Signaling by ALK
- Constitutive Signaling by Aberrant PI3K in Cancer
- IRS-related events triggered by IGF1R
- Signaling by Leptin
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- IRS activation
- Signal attenuation
- Activated NTRK3 signals through PI3K
- Signaling by ALK fusions and activated point mutants
- Growth hormone receptor signaling
- Signaling by LTK
|
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
|
|
Novel |
MAF1 |
MAF1 negative regulator of RNA polymerase III |
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
|
|
|
Novel |
MAPKAP1 |
MAPK associated protein 1 |
- PIP3 activates AKT signaling
- CD28 dependent PI3K/Akt signaling
- VEGFR2 mediated vascular permeability
- Constitutive Signaling by AKT1 E17K in Cancer
- Regulation of TP53 Degradation
- High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
|
|
|
Novel |
MECR |
mitochondrial trans-2-enoyl-CoA reductase |
- Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA
|
|
|
Novel |
MLST8 |
MTOR associated protein MLST8 |
- PIP3 activates AKT signaling
- Macroautophagy
- MTOR signalling
- mTORC1-mediated signalling
- HSF1-dependent transactivation
- Energy dependent regulation of mTOR by LKB1-AMPK
- CD28 dependent PI3K/Akt signaling
- VEGFR2 mediated vascular permeability
- TP53 Regulates Metabolic Genes
- Constitutive Signaling by AKT1 E17K in Cancer
- Regulation of TP53 Degradation
- Regulation of PTEN gene transcription
- Amino acids regulate mTORC1
- High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
|
|
|
Novel |
NPPB |
natriuretic peptide B |
|
|
|
Novel |
NRAS |
NRAS proto-oncogene, GTPase |
- SOS-mediated signalling
- Activation of RAS in B cells
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB4 signaling
- Signaling by SCF-KIT
- Signalling to RAS
- p38MAPK events
- p38MAPK events
- GRB2 events in EGFR signaling
- SHC1 events in EGFR signaling
- Downstream signal transduction
- GRB2 events in ERBB2 signaling
- GRB2 events in ERBB2 signaling
- Tie2 Signaling
- EGFR Transactivation by Gastrin
- DAP12 signaling
- SHC-related events triggered by IGF1R
- FCERI mediated MAPK activation
- NCAM signaling for neurite out-growth
- Ras activation upon Ca2+ influx through NMDA receptor
- VEGFR2 mediated cell proliferation
- CD209 (DC-SIGN) signaling
- Constitutive Signaling by EGFRvIII
- SHC-mediated cascade:FGFR1
- FRS-mediated FGFR1 signaling
- SHC-mediated cascade:FGFR2
- FRS-mediated FGFR2 signaling
- SHC-mediated cascade:FGFR3
- FRS-mediated FGFR3 signaling
- FRS-mediated FGFR4 signaling
- SHC-mediated cascade:FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- Signaling by FGFR3 in disease
- Regulation of RAS by GAPs
- RAF activation
- RAF/MAP kinase cascade
- MAP2K and MAPK activation
- Negative regulation of MAPK pathway
- Neutrophil degranulation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- RAS signaling downstream of NF1 loss-of-function variants
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Insulin receptor signalling cascade
- PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
- MET activates RAS signaling
- Activated NTRK2 signals through RAS
- Erythropoietin activates RAS
- Activated NTRK2 signals through FRS2 and FRS3
- Activated NTRK3 signals through RAS
- FLT3 Signaling
- Constitutive Signaling by Overexpressed ERBB2
- Estrogen-stimulated signaling through PRKCZ
- RAS processing
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 ITD and TKD mutants
- Signaling by RAS GAP mutants
- Signaling by RAS GTPase mutants
|
|
- Adrenal carcinoma
- Acute myeloid leukemia (AML)
- Oral cancer
- Multiple myeloma
- Malignant melanoma
- Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
- Hepatocellular carcinoma
- Thyroid cancer
- Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
|
Novel |
PA2G4 |
proliferation-associated 2G4 |
|
|
|
Novel |
PCNA |
proliferating cell nuclear antigen |
- Translesion synthesis by REV1
- Recognition of DNA damage by PCNA-containing replication complex
- Translesion Synthesis by POLH
- Transcription of E2F targets under negative control by DREAM complex
- Polymerase switching on the C-strand of the telomere
- Processive synthesis on the C-strand of the telomere
- Telomere C-strand (Lagging Strand) Synthesis
- Removal of the Flap Intermediate from the C-strand
- SUMOylation of DNA replication proteins
- Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
- Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
- PCNA-Dependent Long Patch Base Excision Repair
- Translesion synthesis by POLK
- Translesion synthesis by POLI
- Termination of translesion DNA synthesis
- HDR through Homologous Recombination (HRR)
- Gap-filling DNA repair synthesis and ligation in GG-NER
- Dual Incision in GG-NER
- Dual incision in TC-NER
- Gap-filling DNA repair synthesis and ligation in TC-NER
- TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
- Polymerase switching
- Removal of the Flap Intermediate
- Processive synthesis on the lagging strand
- G1/S-Specific Transcription
- E3 ubiquitin ligases ubiquitinate target proteins
|
- Liothyronine
- Acetylsalicylic acid
|
|
Novel |
PDPK1 |
3-phosphoinositide dependent protein kinase 1 |
- GPVI-mediated activation cascade
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Activation of AKT2
- Downstream TCR signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- FCERI mediated NF-kB activation
- Integrin signaling
- CD28 dependent PI3K/Akt signaling
- G beta:gamma signalling through PI3Kgamma
- RSK activation
- VEGFR2 mediated vascular permeability
- VEGFR2 mediated cell proliferation
- CLEC7A (Dectin-1) signaling
- RHO GTPases activate PKNs
- Constitutive Signaling by AKT1 E17K in Cancer
- Regulation of TP53 Degradation
- Estrogen-stimulated signaling through PRKCZ
- Estrogen-stimulated signaling through PRKCZ
- SARS-CoV-1 targets host intracellular signalling and regulatory pathways
- SARS-CoV-2 targets host intracellular signalling and regulatory pathways
- High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
|
- Celecoxib
- Inositol 1,3,4,5-Tetrakisphosphate
- 7-Hydroxystaurosporine
- Bisindolylmaleimide VIII
- Staurosporine
- Bisindolylmaleimide I
- Dexfosfoserine
- 10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3,6-diamine
- 5-HYDROXY-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-2-ONE
- 1-{2-OXO-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-5-YL}UREA
- 2-(1H-imidazol-1-yl)-9-methoxy-8-(2-methoxyethoxy)benzo[c][2,7]naphthyridin-4-amine
- 3-(1H-indol-3-yl)-4-(1-{2-[(2S)-1-methylpyrrolidinyl]ethyl}-1H-indol-3-yl)-1H-pyrrole-2,5-dione
- 3-[1-(3-AMINOPROPYL)-1H-INDOL-3-YL]-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE
- Fostamatinib
|
|
Novel |
PIK3CD |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
- PIP3 activates AKT signaling
- Synthesis of PIPs at the plasma membrane
- Constitutive Signaling by Aberrant PI3K in Cancer
- CD28 dependent PI3K/Akt signaling
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- RET signaling
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Interleukin receptor SHC signaling
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- Signaling by CSF1 (M-CSF) in myeloid cells
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
- Co-stimulation by ICOS
|
- Caffeine
- XL765
- TG100-115
- 2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE
- Idelalisib
- Duvelisib
- Fostamatinib
- Copanlisib
- Umbralisib
|
|
Novel |
PLD2 |
phospholipase D2 |
- Synthesis of PG
- Synthesis of PA
- Role of phospholipids in phagocytosis
- RAC1 GTPase cycle
- RAC2 GTPase cycle
|
- Choline
- Choline salicylate
|
|
Novel |
PLEKHM1 |
pleckstrin homology and RUN domain containing M1 |
|
|
|
Novel |
PPP2R2A |
protein phosphatase 2 regulatory subunit Balpha |
- Initiation of Nuclear Envelope (NE) Reformation
- Cyclin D associated events in G1
- Cyclin A/B1/B2 associated events during G2/M transition
- Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
- Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
- Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
|
- 2,6,8-Trimethyl-3-Amino-9-Benzyl-9-Methoxynonanoic Acid
|
|
Novel |
PREX1 |
phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1 |
- NRAGE signals death through JNK
- G alpha (12/13) signalling events
- RHOA GTPase cycle
- RHOB GTPase cycle
- RHOC GTPase cycle
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOQ GTPase cycle
- RHOG GTPase cycle
- RHOJ GTPase cycle
- RAC3 GTPase cycle
|
|
|
Novel |
PRKAA1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
- Macroautophagy
- Energy dependent regulation of mTOR by LKB1-AMPK
- TP53 Regulates Metabolic Genes
- Regulation of TP53 Activity through Phosphorylation
- Activation of AMPK downstream of NMDARs
- AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274)
|
- Adenosine phosphate
- Adenosine phosphate
- ATP
- Phenformin
- Acetylsalicylic acid
- Fostamatinib
- Fostamatinib
|
|
Novel |
PRKCA |
protein kinase C alpha |
- Calmodulin induced events
- Disinhibition of SNARE formation
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- Regulation of KIT signaling
- EGFR Transactivation by Gastrin
- Inactivation, recovery and regulation of the phototransduction cascade
- Syndecan interactions
- Acetylcholine regulates insulin secretion
- Ca2+ pathway
- Trafficking of GluR2-containing AMPA receptors
- G alpha (z) signalling events
- Depolymerization of the Nuclear Lamina
- HuR (ELAVL1) binds and stabilizes mRNA
- WNT5A-dependent internalization of FZD4
- VEGFR2 mediated cell proliferation
- RHO GTPases Activate NADPH Oxidases
- Response to elevated platelet cytosolic Ca2+
- RET signaling
- ROBO receptors bind AKAP5
- ROBO receptors bind AKAP5
|
- Phosphatidyl serine
- Vitamin E
- Tamoxifen
- Staurosporine
- Dequalinium
- Ingenol mebutate
- Aprinocarsen
- Midostaurin
- Perifosine
- Ellagic acid
- Benzoyl peroxide
- Bryostatin 1
- alpha-Tocopherol succinate
- D-alpha-Tocopherol acetate
|
|
Novel |
PRKN |
parkin RBR E3 ubiquitin protein ligase |
- PINK1-PRKN Mediated Mitophagy
- Regulation of necroptotic cell death
- Josephin domain DUBs
- Aggrephagy
- Amyloid fiber formation
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|